Zanzalintinib + Tecentriq Combination Improved OS in STELLAR-303 Ph 3 Pivotal Trial in Patients with Metastatic CRC June 24, 2025
FDA authorizes Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers June 17, 2025
Leap Therapeutics undergoes strategic restructuring to prioritize clinical development of sirexatamab in CRC resulting in an approximately 50% reduction in workforce May 21, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications May 6, 2025
Enrollment completed in Ph 2 CRDF-004 Trial of Onvansertib in 1L RAS-mutated Metastatic CRC April 22, 2025
First Patient Enrolled in Ph 1b FORTRESS Trial of NG-350A in Locally Advanced Rectal Cancer Patients April 15, 2025
FDA Approves Opdivo + Yervoy as a Treatment for Patients with 1L MSI-H or dMMR Unresectable or Metastatic CRC April 15, 2025
FDA Clears IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic CRC March 18, 2025
FDA accepts Supplemental BLA for Opdivo + Yervoy for Patients with Unresectable or Metastatic MSI-H or MRD CRC March 4, 2025
Investigator Initiated Ph 2 Trial for Neoadjuvant Muzastotug (ADG126) in CRC Announced February 28, 2025
Progress and Expansion of Clinical Collaboration Program for ADG126 (muzastotug) + KEYTRUDA combo in MSS CRC announced February 10, 2025
BRAFTOVI Combination Regimen Significantly Improved PFS and OS in Ph 3 BREAKWATER Trial February 5, 2025
Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study of sirexatamab (DKN-01) Reported February 4, 2025
ASCO GI 2025: Encouraging Results from Ph 1b/2 STELLAR-001 Trial of Zanzalintinib +/- Immune Checkpoint Inhibitor in Metastatic CRC announced January 28, 2025
ASCO GI 2025: Results from CheckMate -8HW Analysis of Opdivo + Yervoy Compared to Opdivo Monotherapy in Patients with MSI-H or MMRD Metastatic CRC announced January 28, 2025
ASCO GI 2025: Initial Ph 2 Data for Vilastobart (XTX101) in Combination with Atezolizumab in Patients with MSS CRC announced January 28, 2025
ASCO GI 2025: Results from Ph 3 CALGB (Alliance) / SWOG 80702 Clinical Trial in CRC announced January 28, 2025
ASCO GI 2025: BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic CRC from the Ph 3 BREAKWATER trial January 28, 2025
FDA Approves Lumakras® (Sotorasib) + Vectibix® (Panitumumab) For Chemorefractory KRAS G12C-Mutated Metastatic CRC January 21, 2025
Invikafusp Alfa (STAR0602) Receives US FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic TMB-H CRC January 15, 2025
